A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Public ClinicalTrials.gov record NCT03987451. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Investigation of Efficacy and Safety of Semaglutide s.c. Once-weekly Versus Placebo in Subjects With Non-alcoholic Steatohepatitis and Compensated Liver Cirrhosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is decided by chance. The study will last for about 61 weeks in total. Participants will have 10 clinic visits and 3 phone calls with the study doctor or staff during the study. Some of the clinic visits may be spread over more days. Participants will need to inject themselves with medicine under the skin. Participants will have to do this once a week for 48 weeks. The study includes magnetic resonance imaging (MRI) scans of the liver, 1 or 2 liver tissue samples, ultrasound scans of the stomach and a possible examination of the food pipe. For some tests participants may need to remove some items of clothing. Participants will stop in the study if the doctor thinks that there are any risks for their health. The information collected from participants during the study may help them and other patients with NASH in the future. Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
Study identification
- NCT ID
- NCT03987451
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 18, 2019 (Actual)
- Primary completion
- Apr 22, 2021 (Actual)
- Completion
- Jun 10, 2021 (Actual)
- Last update posted
- May 29, 2024
2019 – 2021
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Liver Health | Chandler | Arizona | 85224 | — |
| The Institute for Liver Health dba Arizona Liver Health | Peoria | Arizona | 85381 | — |
| Southern California Research Center | Coronado | California | 92118 | — |
| Altman Clinical Translational Research Institute | La Jolla | California | 92037 | — |
| Inland Empire Clinical Trials LLC | Rialto | California | 92377 | — |
| Excel Medical Center Clinical Trials, LLC | Boca Raton | Florida | 33434 | — |
| University of Florida-CTRB | Gainesville | Florida | 32610 | — |
| University of Miami/Schiff Center for Liver Diseases | Miami | Florida | 33136 | — |
| Piedmont Research Institute | Atlanta | Georgia | 30309 | — |
| Gastrointestinal Specialists of Georgia | Marietta | Georgia | 30060 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Digestive Research Alliance of Michiana | South Bend | Indiana | 46635 | — |
| University of Kentucky Hospital | Lexington | Kentucky | 40508 | — |
| Mercy Medical Center, GI Research | Baltimore | Maryland | 21202 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Duke University | Durham | North Carolina | 27710 | — |
| Gastroenterology Center For The Mid-South | Germantown | Tennessee | 38138 | — |
| Digestive Health Research - Tristar Summit Medical Center | Hermitage | Tennessee | 37076 | — |
| Quality Medical Research | Nashville | Tennessee | 37211 | — |
| Texas Clinical Research Institute, LLC | Arlington | Texas | 76012 | — |
| The University of Texas Southwestern Medical Center - Dallas | Dallas | Texas | 75390-8887 | — |
| American Research Corporation at the Texas Liver Institute | San Antonio | Texas | 78215 | — |
| VCU Health Systems | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03987451, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 29, 2024 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03987451 live on ClinicalTrials.gov.